Stockreport

Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study

Neumora Therapeutics, Inc.  (NMRA) 
PDF WATERTOWN, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline [Read more]